Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 62 of 2749 for:    Neoplasms | Neuroendocrine Tumors

Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin (DUNE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03095274
Recruitment Status : Recruiting
First Posted : March 29, 2017
Last Update Posted : November 28, 2018
Sponsor:
Information provided by (Responsible Party):
Grupo Espanol de Tumores Neuroendocrinos

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : April 2020
  Estimated Study Completion Date : April 2020